// Sector
Medical
Bionicland's Medical stream tracks AI-assisted diagnostics, biotech R&D, surgical robotics, drug-discovery pipelines, and the regulatory shifts shaping clinical deployment. Every article is synthesized from primary reporting and reviewed under our editorial policy.
32 synthesized articles in this stream — 32 in the permanent archive.
// Archive
32 logged
Epic Systems' Walled Garden Is Under Federal Scrutiny
Epic runs the software behind American medicine. Now the FTC is investigating whether its tight grip on data and employees is illegal. This is about more than software; it's about control.

Eli Lilly's War on the Black Market for a Miracle Weight-Loss Drug
A drug that delivers astonishing weight loss has spawned a massive gray market. Now, the pharma giant that makes it is fighting back, and the supply chain is about to get ugly.

The FDA Just Blocked a Cancer Drug Because the Factory Failed
A promising radiopharmaceutical was rejected, but not because the science was bad. The problem was manufacturing, handing a massive advantage to the market incumbent, Novartis. The future of nuclear medicine is a logistics problem.

The NIH Is Closing Its Golden Ticket Grant to Foreign Scientists
The 'Pathways to Independence' award was a crucial lifeline for international researchers in the U.S. Now, the NIH plans to cut it, threatening to send a generation of talent to its global competitors.

Anthropic's New AI Is Already In The Lab
Anthropic's new AI won't write you a poem. It might help find you a cure. The deployment of Claude Science into biopharma labs changes the drug discovery game on a fundamental level.

The Government Is Building a Factory for One-Off Gene Cures
Roche just killed its ambitious Huntington's program. In its place, a government agency is funding a radical new plan: a bespoke production line for therapies the free market will never build.

Your 500 Siblings You Never Knew
Consumer genetics kits and a global market for sperm created a generation with hundreds of biological half-siblings. Now, European regulators are trying to put the brakes on industrial-scale reproduction.

The White House Wants Your Generic Drugs Made in America. Again.
Washington just told Big Pharma to bring its factories home. This isn't about jobs. It's about whether your antibiotics are a strategic national asset or a geopolitical liability.

Telehealth's GLP-1 Gold Rush Is Bypassing The Doctor
A new secret shopper study reveals the frictionless reality of getting weight-loss drugs online. The clinical oversight is not the story. The speed of the transaction is.

This Box Keeps Donor Eyeballs Alive After Death
The first whole-eye transplant was a surgical success but a functional failure. A new perfusion device keeps donor eyes 'alive,' potentially making sight-restoring transplants a reality.

SpudCell Is a Weird Name for an Unsettling Future
Forget the incremental drug updates. A new synthetic biological chassis just appeared on the radar, and it looks less like a cell and more like a programmable bio-Lego.

The Fight Over Who Answers a Crisis Hotline
The 988 crisis hotline for LGBTQ+ youth is being rebooted. But the nonprofit that pioneered the service, The Trevor Project, is being frozen out of the system it helped build.

Stripe and OpenAI Are Funding a War on the Common Cold
A group of software engineers and AI labs are funding a $500 million nonprofit to prevent respiratory infections. This isn't a moonshot from big pharma; it's a bet from Silicon Valley.

The $89 Million Rubber Stamp That Faked Medical Care
A Texas doctor allegedly ran an $89 million fraud by billing for heart screenings he never actually reviewed. A system built on trust finds its most dangerous vulnerability in a single signature.

The Race to Implant Is Quietly Accelerating
For decades, brain-computer interfaces were a lab curiosity. New data shows the number of human trials has more than doubled in a year, and a commercial arms race is in full swing.

Your Body Has an API. Science Is Finally Mapping It.
Your body sends your brain 11 million bits of data every second. You're conscious of about 60. Decoding the rest is the new frontier in medicine, wellness, and control.

The BCI Has Its First Power User, and He Has a Job
For years, brain-computer interfaces were a lab demo. Now, a man with ALS has used his for thousands of hours to speak, work, and live. This is not a trial run anymore.

Cellular Reprogramming Just Entered Human Trials
A biotech just injected rejuvenation factors into a human eyeball to treat glaucoma. The real target isn't the eye. It's aging itself.

Molecular Glue Is Pharma’s Play for the Undruggable
For decades, most diseases were untouchable. Novartis is now betting billions on a way to hijack the cell’s own machinery to destroy them from within. It’s a profound change in how we design drugs.

The End of the Daily Pill for HIV
For decades, living with HIV meant a strict daily regimen. A new once-weekly pill from Merck and Gilead aims to break that cycle, changing the calculus of living with a chronic disease.

That New Ebola Model Is More Than a Number. It's a Memory.
The CDC just put a number on a worst-case Ebola outbreak: 20,000 cases. The math is simple, and the memory of the last time we faced a number like that is the real story.

The FDA Is Not Studying a Pill, It's Building a Weapon
Mifepristone has been settled science for decades. A new FDA safety study isn't about health. It's about using the agency's own rules to control access.

Your Watch Knows If You Go Outside. An App Wants To Sell You Why.
Apple Watch passively tracks your time in the sun. A third-party app is now layering that data over your heart stats, selling wellness insights Apple won't.

When the Smart Bomb Fails, Send in the Sniper
Novartis's Pluvicto was a breakthrough radiopharmaceutical. But tumors adapt. Convergent Therapeutics is betting a more potent atomic payload can kill the cancer that survives.

Prostate Cancer's New Protocol Isn't a Cure, It's an Edge
A new trial just gave men with high-risk prostate cancer a third, more aggressive option. It’s not a miracle drug, but a new playbook that gives surgery a fighting chance against relapse.

Pfizer's Drug Pipeline Now Flows Through China
Big Pharma's labs are running dry. To fill a pipeline worth billions, Pfizer is shopping for novel cancer drugs not in Boston or San Diego, but in Beijing.

The Touch Network: Psyonic Bridges the Gap Between Silicon and Human Nerve
The Psyonic Blueprint: A San Diego cybernetics firm has officially deployed the world's first multi-touch bionic hand on the commercial market—and they wired it straight into Medicare. The sensory loop is finally closed.

Wetware Patch: Retro Biosciences Scales Cellular Reprogramming Pipeline to Combat Biological Decay Lattices
Silicon Valley ventures drive $1.8 billion valuations into cellular longevity substrates while federal NIH oversight faces tightening fiscal constraints and pharmaceutical lobbying shifts.

Chemistry by Chatbot
SandboxAQ brings AI models to Claude, redefining drug discovery. The cost of progress is human expertise.

Posture Revolution
A new offline desk gadget tracks posture and movement without invading your privacy. Deep Care's Isa device is a game-changer for remote workers.

Neural Implants Clear the FDA Gauntlet: Inside the Silicon Eating Into the Cortex
Three brain-computer interfaces just punched through the FDA's de novo pathway. The story isn't the approvals — it's the thermodynamic tightrope of running compute inside a living skull.

Wearable Glucose Monitors Go Mainstream — Without a Prescription
Abbott Lingo and Dexcom Stelo are now over-the-counter. What the data actually tells healthy users about diet and sleep.